Analyze state requirements for safe prescribing and prescription monitoring

    Practicum Journal: Safe Prescribing

There is probably no greater responsibility that the psychiatric mental health nurse practitioner (PMHNP) assumes than the responsibility of prescribing medications. While someone can be harmed by psychotherapy, the level and intensity of the harm generally does not come to the same level of harm that can occur from improper prescribing. The PMHNP must understand his/her responsibility both at a state and federal level when it comes to prescribing medications.

In this Practicum Journal Assignment, you will explore the legalities associated with prescribing controlled substances, as well as what a DEA number is, how to obtain one, and, most importantly, how to prescribe controlled substances in your state.

Learning Objectives

· Analyze roles of the Drug Enforcement Administration

· Analyze PMHNP responsibilities when issued a DEA number

· Analyze DEA number application procedures

· Analyze state requirements for safe prescribing and prescription monitoring

· Analyze PMHNP responsibilities for safe prescribing and prescription monitoring

· Analyze Schedule II-V drug levels

                                        ASSIGNMENT

To prepare for this Practicum Journal:

· Review the Learning Resources.

In 2-3 pages:

· Describe the role of the Drug Enforcement Administration (DEA) as it pertains to

the Psychiatric mental health nurse practitioner (PMHNP).

· Explain your responsibilities when having a DEA number.

· Explain how you apply for a DEA number.

· Explain your state’s requirements (TEXAS) for a safe prescribing and prescription monitoring program. Explain your responsibility as a PMHNP to follow these requirements.

· Provide an example of a drug you may prescribe from each of the Schedule II-V drug levels.

N: B PLEASE INCLUDE INTRODUCTION, CONCLUSION AND REFERENCES LESS THAN 5 YEARS OLD

                                                            Learning Resources

Required Readings

Stahl, S. M. (2014). Prescriber’s Guide: Stahl’s Essential Psychopharmacology (5th ed.). New York, NY: Cambridge University Press.

http://ezp.waldenulibrary.org/login?url=http://stahlonline.cambridge.org/

To access information on specific medications, click on The Prescriber’s Guide, 5th Ed. tab on the Stahl Online website and select the appropriate medication.

 

Depression

Premenstrual    dysphoric disorder

Seasonal    affective disorder (MDD with Seasonal Variation)

 

agomelatine
amisulpride
amitriptyline
amoxapine
amphetamine (d)
amphetamine (d,l)
aripiprazole (adjunct)
asenapine
atomoxetine
bupropion
buspirone (adjunct)
citalopram
clomipramine
cyamemazine
desipramine
desvenlafaxine
dothiepin
paroxetine
phenelzine
protriptyline

quetiapine (adjunct)
reboxetine
selegiline
sertindole
sertraline
sulpiride
tianeptine
tranylcypromine
triiodothyronine
trazodone
trimipramine
venlafaxine
vilazodone
vortioxetine
doxepin
duloxetine
escitalopram
fluoxetine
flupenthixol
fluvoxamine

iloperidone
imipramine
isocarboxazid
ketamine
lisdexamfetamine
lithium (adjunct)
l-methylfolate (adjunct)
lofepramine
lurasidone
maprotiline
methylphenidate (d)
methylphenidate (d,l)
mianserin
milnacipran
mirtazapine
moclobemide
modafinil (adjunct)
nefazodone
nortriptyline
olanzapine

citalopram
desvenlafaxine
escitalopram
fluoxetine
paroxetine
sertraline
venlafaxine

bupropion

 

Drug Enforcement Administration. (n.d.). Drug schedules. Retrieved June 14, 2016, from https://www.dea.gov/druginfo/ds.shtml